What happened with JAZZ today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Jazz Pharmaceuticals’ biggest products treat sleep disorders and certain forms of epilepsy. Xywav treats narcolepsy and idiopathic hypersomnia, while Epidiolex, called Epidyolex in some markets, treats seizures associated with specific rare conditions. Together, these medicines account for most product sales, with Xywav the largest contributor. Jazz also sells cancer medicines, including Rylaze for certain leukemia and lymphoma patients. Most revenue comes from the United States.
Pharmacies and distributors buy Jazz’s medicines and deliver them to patients or treatment centers. Its largest customer, ESSDS, accounts for a substantial share of revenue and is the sole certified U.S. pharmacy for Xywav and the related sleep medicine Xyrem. FDA rules require these drugs to be shipped directly to enrolled patients or caregivers through that pharmacy; retail pharmacies cannot stock them, and prescribers must also enroll in the safety program.
Sales depend on doctors prescribing the medicines and government and commercial health plans covering treatment. Coverage restrictions can delay access or steer patients toward cheaper alternatives. Jazz remains meaningfully dependent on its sleep medicines, which already face competition from branded Lumryz and generic high-sodium oxybate products.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Missing from this list are Hikma, important to Jazz Pharmaceuticals’ oxybate royalties and competition, and UCB, an epilepsy rival to watch for Epidiolex adoption.
Alkermes Inc. plc competes directly for Jazz Pharmaceuticals’ U.S. narcolepsy patients, selling once-nightly Lumryz against Xywav and Xyrem after acquiring Avadel. Watch Lumryz sales for pressure on Jazz’s oxybate medicines.
Harmony Biosciences Holdings, Inc. sells WAKIX through specialty distributors to narcolepsy patients, competing with Jazz Pharmaceuticals’ Xywav and Xyrem for prescriptions and payer coverage. Watch whether coverage favors WAKIX over Jazz’s medicines.
Amneal Pharmaceuticals, Inc. sells generic sodium oxybate that competes with Jazz Pharmaceuticals’ Xyrem and Xywav for U.S. narcolepsy patients and places on insurers’ covered-drug lists. Its volume-limited authorized-generic rights, which paid Jazz royalties, ended in 2025; watch its own generic for pressure on Jazz’s branded net prices and coverage.
Axsome Therapeutics, Inc sells Sunosi for narcolepsy-related daytime sleepiness and develops reboxetine, competing with Jazz Pharmaceuticals’ sleep-disorder medicines. Watch Sunosi use among narcolepsy patients and reboxetine’s development, rather than Axsome’s combined sales across depression, sleepiness and migraine.
Takeda Pharmaceutical Company Limited’s experimental narcolepsy medicines could challenge the treatment market supporting Jazz Pharmaceuticals’ Xywav and Xyrem. Watch development of its drugs that activate orexin receptors: Xywav alone accounted for 41% of Jazz’s net product sales in 2025.
Zymeworks Inc. gives Jazz Pharmaceuticals rights to develop and sell Ziihera, earning milestone payments and royalties tied to Jazz’s progress with the cancer medicine. Its Ziihera-related payments offer a window into Jazz’s development and commercialization progress.
Teva Pharmaceutical Industries Limited is seeking approval to sell generic Xywav, challenging a medicine that supplied 41% of Jazz Pharmaceuticals’ net product sales in 2025. Watch the generic application’s progress, not an assumed launch.
Amgen Inc sells tarlatamab in direct competition with Jazz Pharmaceuticals’ Zepzelca for U.S. second-line small-cell lung cancer treatment. Watch tarlatamab’s place in treatment pathways for pressure on Zepzelca, which contributed 8% of Jazz’s net product sales in 2025.
Ligand Pharmaceuticals Inc. earns royalties linked to Jazz Pharmaceuticals’ sales of the leukemia medicine Rylaze, whose licensed rights rely on Ligand’s Pfenex technology. That ties Ligand’s royalty business to Jazz’s success selling Rylaze.
Stoke Therapeutics, Inc. is developing a treatment aimed at Dravet syndrome’s genetic cause that could change choices for patients using Jazz Pharmaceuticals’ Epidiolex. Watch its clinical-trial progress rather than current drug sales: Epidiolex/Epidyolex supplied 26% of Jazz’s net product sales in 2025.
Alkermes Inc. plc earningsALKS
Alkermes’s report will show how Lumryz is selling, and what that means for competition with Jazz’s Xywav and Xyrem.
Look at Alkermes’s reported Lumryz sales. Growth would show that the once-nightly oxybate is reaching more people with narcolepsy, potentially adding pressure as Jazz seeks patients and insurer coverage for its medicines; weak sales would show less evidence of that momentum. The question is whether Lumryz is becoming a stronger alternative.
Fed Interest Rate Decision
Jazz Pharmaceuticals’ debt costs can change when the Fed adjusts the economy’s benchmark interest rate, because some of its borrowings have variable rates.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates can raise interest expense on borrowings that reprice and make new borrowing costlier, leaving less cash for Jazz’s operations and investment.
If it comes in below expectations
Lower rates can reduce interest expense on borrowings that reprice and make new borrowing cheaper, leaving more cash for Jazz’s operations and investment.
Amneal Pharmaceuticals, Inc. earningsAMRX
Amneal’s report can show whether its generic sodium oxybate is gaining ground against Jazz’s Xywav and Xyrem on price and insurer coverage.
Look for Amneal’s disclosures on sales of its own generic sodium oxybate, not the volume-limited authorized-generic business that ended in 2025 and paid royalties to Jazz. Stronger sales of its own generic would suggest it may be winning patients through price or insurer coverage, putting pressure on Jazz’s branded sales or net prices; weak sales would offer less evidence of that pressure. The question is whether Amneal’s own generic is gaining ground.
Amgen Inc earningsAMGN
Amgen’s report can show whether tarlatamab is gaining use, and how much pressure it may put on Jazz’s Zepzelca in small-cell lung cancer.
Watch Amgen’s comments on tarlatamab sales and use, especially its place in small-cell lung cancer treatment. Broader use would mean more patients may receive a medicine that competes with Zepzelca, increasing pressure on Jazz; limited use would provide less evidence of that pressure. The question is whether tarlatamab is becoming a more common treatment choice.
Stoke Therapeutics, Inc. earningsSTOK
Stoke’s report can show whether its Dravet syndrome treatment is advancing toward a possible future alternative to Jazz’s Epidiolex.
Look for updates on clinical trials of Stoke’s Dravet syndrome treatment, not just current drug sales. Progress would bring a treatment aimed at the genetic cause closer to becoming an option alongside Epidiolex for some patients; little progress would leave that possibility more distant. This speaks to future alternatives, not a current effect on Epidiolex sales.
Jazz Pharmaceuticals, Inc. earningsThis company
Jazz’s report will show whether growth in Xywav and Epidiolex can keep offsetting falling Xyrem sales.
Read Xywav and Xyrem sales and volume together, then check whether Epidiolex is still growing. If Xywav grows as Xyrem falls and Epidiolex also grows, Jazz’s other leading products are taking up more of the sales Xyrem is losing. If Xywav slows while Xyrem keeps falling and Epidiolex does not make up the gap, the handoff between products is not yet enough. The question is whether growth replaces the sales being lost.
